Anne Sophie Kubasch
@ASKubasch
Followers
1K
Following
556
Media
54
Statuses
187
MD, Clinician Scientist #Hematology | #CellularTherapy | #Hemostaseology Unit, University Hospital Leipzig @UKL_Leipzig |
Leipzig, Deutschland
Joined September 2009
Yesterday, we presented the results of the LUCAS and CANFIRE trials at #ASH 2024 in San Diego (Poster ID: 199032). Our studies investigated IRAK4 and IL-1β blockade in lower-risk #MDS to address #inflammation-driven ineffective hematopoiesis. @ASH_hematology
13
9
177
Do you want to hear about the latest breakthroughs in digital medicine & artificial intelligence in cancer care? Register here for the upcoming Shaping the Future of Medicine symposium taking place on 24 & 25 Sept: 👉 https://t.co/voXjqqFxK6 👈 #AI #HemOnc #LLMs @ShapFutureMed
0
2
3
Don‘t miss our @ShapFutureMed symposium in Leipzig on Sept 24-25,2024. @Google’s Vivek Natarajan will be there in person and share his invaluable insights on the transformative role of artificial intelligence in healthcare. https://t.co/NieI4wFz1G
#LLMs #STFOM2024 @GoogleHealth
1
3
9
#iwMDS24 | Join @ASKubasch of @UKL_Leipzig discusses new digital tools in hematology @VJHemOnc #iwMDS24 #MDSsm #MDS
1
4
9
CONGRESS | #EHA2024 Anne Sophie Kubasch @ASKubasch @UKL_Leipzig presented long-term data showing that MRD-guided pre-emptive treatment with Aza delayed relapse in patients with MRD-positivity in the phase II open-label RELAZA2 study in patients with MDS or AML. ▪️ After median
0
6
24
Enjoyed reconnecting with these two fantastic colleagues, @sanamloghavi and @KatjaSockel, during the #EHA2024 meeting in Madrid this week 🇪🇸 @EHA_Hematology
0
0
44
At the @EHA_Hematology Association meeting in #Madrid, we had the privilege of presenting the long-term follow-up results of our #RELAZA2 study, which focuses on the efficacy of #azacitidine in treating measurable residual disease (#MRD) in #MDS and #AML! #EHA2024
0
0
25
CONGRESS | #EHA2024 Anne Sophie Kubasch @ASKubasch @UKL_Leipzig presents long-term follow-up of the phase II open-label RELAZA2 study of Aza in the treatment of MRD in MDS and AML. MRD-guided pre-emptive treatment with Aza was found to be efficacious in preventing/delaying
0
2
11
Just released! Please check out our @ShapFutureMed #FeaturingCancer preliminary program! Join us and register here: https://t.co/MFK11fXYFM
0
1
2
The preliminary program for our @ShapFutureMed #NextGenCancerInnovater Symposium is now online! Come and join us and register here: https://t.co/MFK11fYwvk
0
1
3
The countdown begins, register now and join us! #STFOM
Registration for #STFOM2024 starting September 24 until 25, 2024 is now open. Stay tuned for regular program updates in the coming weeks! Please register here: https://t.co/O5bnbCuny4
0
0
1
Thrilled to see our i4MDS position paper out in @Hemasphere_EHA today. This work was led by @KordastiL and provides a framework for immune monitoring in patients with #MDSsm and related conditions. The aim of i4MDS is to enhance MDS stratification, identify predictive markers of
4
29
106
Yesterday, #Chemnitz hosted the esteemed #Saxon #AI #Congress, which featured a robust discussion on #Saxony's #AI #strategy and the release of the latest study assessing #Saxony's #AI landscape: https://t.co/L4yveEW2OW
@SachsenDe @MPKretschmer
0
0
5
During the Leipzig Hematology Symposium #LHS, we discussed how to illuminate the #patient pathway towards more #personalized, efficient, and accessible #cancer #care through the integration of #digital #technologies.
0
1
8
Verbesserter Zugang zu innovativen Therapien durch Netzwerke: Berlin – Vom Zugang zu innovativen Therapien in der klinischen Praxis profitieren medizinisch nicht nur Patienten, sondern wirtschaftlich auch… https://t.co/2MEdO43pVE
#SaxoCell #Forschung #Therapien #Innovation
5
1
2
This week I had the opportunity to meet with Prof Matteo Della Porta and his team at the #AI Center, @HUNIMED Research Hospital. The synergy between #technology, #hematology and the groups commitment to #innovation was a really enriching experience for future #collaborations.
2
0
31
I recently had the honor of meeting Prof Peter Greenberg in his office at @StanfordMed! #MDS #hematology
2
4
102
Is bemcentinib beneficial for patients with higher-risk #MDS or acute myeloid leukemia who are relapsed/refractory following hypomethylating agent treatment? Read our summary of the phase II BERGAMO trial 👉 https://t.co/jPYjKBbmBF.
#MDSsm #leusm #MedicalEducation
0
1
4